332 related articles for article (PubMed ID: 38005253)
1. Study Models of Drug-Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels.
Veiga-Matos J; Morales AI; Prieto M; Remião F; Silva R
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005253
[TBL] [Abstract][Full Text] [Related]
2. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
[TBL] [Abstract][Full Text] [Related]
3. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.
Elmeliegy M; Vourvahis M; Guo C; Wang DD
Clin Pharmacokinet; 2020 Jun; 59(6):699-714. PubMed ID: 32052379
[TBL] [Abstract][Full Text] [Related]
4. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
Zhou SF
Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
[TBL] [Abstract][Full Text] [Related]
5. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
Bansal T; Jaggi M; Khar RK; Talegaonkar S
J Pharm Pharm Sci; 2009; 12(1):46-78. PubMed ID: 19470292
[TBL] [Abstract][Full Text] [Related]
6. Newly Synthesized Oxygenated Xanthones as Potential P-Glycoprotein Activators:
Martins E; Silva V; Lemos A; Palmeira A; Puthongking P; Sousa E; Rocha-Pereira C; Ghanem CI; Carmo H; Remião F; Silva R
Molecules; 2019 Feb; 24(4):. PubMed ID: 30781374
[TBL] [Abstract][Full Text] [Related]
7. Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications.
Zamek-Gliszczynski MJ; Patel M; Yang X; Lutz JD; Chu X; Brouwer KLR; Lai Y; Lee CA; Neuhoff S; Paine MF; Sugiyama Y; Taskar KS; Galetin A
Clin Pharmacol Ther; 2021 Jan; 109(1):55-64. PubMed ID: 32460379
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules.
Vormann MK; Gijzen L; Hutter S; Boot L; Nicolas A; van den Heuvel A; Vriend J; Ng CP; Nieskens TTG; van Duinen V; de Wagenaar B; Masereeuw R; Suter-Dick L; Trietsch SJ; Wilmer M; Joore J; Vulto P; Lanz HL
AAPS J; 2018 Aug; 20(5):90. PubMed ID: 30109442
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.
Taskar KS; Yang X; Neuhoff S; Patel M; Yoshida K; Paine MF; Brouwer KLR; Chu X; Sugiyama Y; Cook J; Polli JW; Hanna I; Lai Y; Zamek-Gliszczynski M;
Clin Pharmacol Ther; 2022 Sep; 112(3):573-592. PubMed ID: 35612761
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
11. Psychotropic drug-drug interactions involving P-glycoprotein.
Akamine Y; Yasui-Furukori N; Ieiri I; Uno T
CNS Drugs; 2012 Nov; 26(11):959-73. PubMed ID: 23023659
[TBL] [Abstract][Full Text] [Related]
12. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
13. Approaches to minimize the effects of P-glycoprotein in drug transport: A review.
Husain A; Makadia V; Valicherla GR; Riyazuddin M; Gayen JR
Drug Dev Res; 2022 Jun; 83(4):825-841. PubMed ID: 35103340
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.
Lin JH
Adv Drug Deliv Rev; 2003 Jan; 55(1):53-81. PubMed ID: 12535574
[TBL] [Abstract][Full Text] [Related]
15. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD
Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284
[TBL] [Abstract][Full Text] [Related]
16. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
[TBL] [Abstract][Full Text] [Related]
17. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
Ozgür B; Saaby L; Janfelt C; Langthaler K; Eneberg E; Jacobsen AM; Badolo L; Montanari D; Brodin B
Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
[TBL] [Abstract][Full Text] [Related]
18. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
19. Renal Drug Transporters and Drug Interactions.
Ivanyuk A; Livio F; Biollaz J; Buclin T
Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
[TBL] [Abstract][Full Text] [Related]
20. Xanthones as P-glycoprotein modulators and their impact on drug bioavailability.
Silva V; Gil-Martins E; Silva B; Rocha-Pereira C; Sousa ME; Remião F; Silva R
Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):441-482. PubMed ID: 33283552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
